HealthQuill Non-small Cell Lung Cancer
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat a type of lung cancer.
Drugs Health Pharma

FDA rejects Daiichi, Merck, antibody-drug conjugate application

The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.

Read More
Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression after five years, according to company data.
Drugs Health Pharma

Pfizer’s drug helps people with rare lung cancer live longer, data shows

Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression.

Read More
The USFDA has cleared AstraZeneca’s lung cancer drug Tagrisso with chemotherapy for treatment in adult patients.
Drugs Health Pharma

AstraZeneca’s non-small lung cancer therapy gets FDA clearance

HQ Team February 17, 2024: The USFDA has cleared AstraZeneca’s Tagrisso with chemotherapy for treatment in adult patients with non-small cell lung cancer..

Read More
The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer.
Drugs Health Pharma

FDA nod for Pfizer’s combination therapy for non-small cell cancer

HQ Team October 12, 2023: The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer. The FDA.

Read More
AstraZeneca’s lung cancer drug, Tagrisso, reduced the risk of death by 51% in the early stages of the disease, according to a company statement.
Drugs Health Medical Pharma

AstraZeneca’s drug cuts risk of lung cancer death by 51%, trials show

HQ Team June 5, 2023: AstraZeneca’s lung cancer drug, Tagrisso, reduced the risk of death by 51% in the early stages of the.

Read More
X